VCYT News

Latest breaking news and updates for VCYT stock.

Track all markets on TradingView

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces New Study in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

How does this breakthrough compare to competitor genomic tests and could it shift market share or reimbursement dynamics? What is the expected timeline and scale for commercial uptake of the Decipher test in metastatic prostate cancer treatment protocols? How will the positive Cell study results affect Veracyte's valuation and short-term stock momentum?
Clinical trials
21 days ago
Read more businesswire

Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

What is the potential market size for the Percepta Nasal Swab lung cancer test compared with existing diagnostics, and how will Veracyte capture market share? When can we expect preliminary data or results from the NIGHTINGALE trial, and how might that influence the share price? How will the completion of enrollment in the NIGHTINGALE trial affect Veracyte's short‑term cash flow and valuation?
Clinical trials
22 days ago
Read more businesswire

Veracyte Announces Second Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the second quarter ended June 30, 2025. “Tes...

What are the risks or upside scenarios if Veracyte fails to meet its projected volume growth targets for the remainder of 2025? How might the sustained >25% YoY growth for Decipher influence future pricing, reimbursement, or partnership negotiations? What is the potential impact of the Q2 results on institutional and retail analyst sentiment toward Veracyte?
Earnings
about 1 month ago
Read more businesswire